Clinical approach to lupus nephritis: Recent advances

European Journal of Internal Medicine

Volumn 20, Issue 5, 2009, Pages 447-453

  Molino, C ^a   Fabbian, F ^b   Longhini, C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Histology; Lupus nephritis; Mycophenolate mofetil; SLE

Indexed keywords

ABATACEPT; ABETIMUS; AUTOANTIBODY; AZATHIOPRINE; BELATACEPT; BELIMUMAB; CARDIOLIPIN ANTIBODY; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA POLYMERASE; EPRATUZUMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ALOPECIA; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTHRALGIA; ATHEROSCLEROSIS; B LYMPHOCYTE ACTIVATION; CAUSE OF DEATH; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; COMORBIDITY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; ELECTRON MICROSCOPY; ENVIRONMENTAL FACTOR; FOLLOW UP; GLOMERULONEPHRITIS; HEMATURIA; HEREDITY; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NEPHROTOXICITY; OVARY INSUFFICIENCY; PANCREATITIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; REMISSION; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; PROGNOSIS; RISK FACTORS;

EID: 68949192362     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.12.018     Document Type: Review

References (86)

1. Cross J., and Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol. 19 (2005) 785-798
2. Cameron J.S. Lupus nephritis. J Am Soc Nephrol 10 (1999) 413-424
3. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 (2004) 241-250
4. Bono L., Cameron J.S., and Hicks J.A. The very long-term prognosis and complications of lupus nephritis and its treatment. QJ Med 4 (1999) 211-218
5. Kang I., and Park S.H. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15 (2003) 528-534
6. Zonana-Nacach A., Barr S.G., Madger L.A., and Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43 (2000) 1801-1808
7. Bernatsky S., Ramsey-Goldman R., and Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am. 31 (2005) 387-402
8. Cameron J.J.S. Clinical manifestations of lupus nephritis. In: Lewis E.J., Schwartz M.M., and Korbet S.M. (Eds). Lupus Nephritis (1999), Oxford University Press, Oxford 159-184
9. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., and Rohde R.D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 35 (2000) 904-914
10. Cameron J. Rheumatology and the kidney. In: Davison A., Cameron J.S., Grunfeld J.P., Kerr D.N.S., Ritz E., and Winearls C.G. (Eds). Oxford Textbook of Clinical Nephrology. 2nd edn. 5 (1997), Oxford University Press, Oxford 2709-2716
11. Korbet S.M., Lewis E.J., Schwartz M.M., et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (2000) 904-914
12. Seligman V.A., Lum R.F., Olson J.L., Li H., and Criswell L.A. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 112 (2002) 726-729
13. Hopkinson N.D., Jenkinson C., Muir K.R., Doherty M., and Powell R.J. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis. 59 (2000) 116-119
14. Houng D.L., Papo T., Beaufils H., Wechsler B., Blétry O., Baumelou A., et al. Renal involvement in systemic lupus erythematosus. Medicine. 78 (1999) 148-166
15. Danchenko N., Satia J.A., and Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15 (2006) 308-318
16. Lea J. Lupus nephritis in African Americans. Am J Med Sci 323 (2002) 85-89
17. Clynes R., Dumitru C., and Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279 (1998) 1052-1054
18. Hahn B.H. Mechanisms of disease: antibodies to DNA. N Engl J Med 338 (1998) 1359-1368
19. Munoz L.E., Gaipl U.S., Franz S., Sheriff A., Voll R.E., Kalden J.R., et al. SLE-a disease of clearance deficiency?. Rheumatology 44 (2005) 1101-1107
20. Baumann I., Kolowos W., Voll R.E., Manger B., Gaipl U., Neuhuber W.L., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46 (2002) 191-201
21. Graham R.R., Kozyrev S.V., Baechler E.C., Reddy M.V., Plenge R.M., Bauer J.W., et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38 (2006) 550-555
22. Fujii Y., Fujii K., and Tanaka Y. Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. Autoimmun Rev. 5 (2006) 143-144
23. Fries J.W., Mendrick D.L., and Rennke H.G. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 34 (1988) 333-345
24. Berden J.H.M. Lupus nephritis. Kidney Int. 52 (1997) 538-558
25. Schwartz M.M. The pathology of lupus nephritis. Semin Nephrol. 27 (2007) 22-34
26. Austin H.A., and Illei G.G. Membranous lupus nephritis. Lupus. 14 (2005) 65-71
27. Appel G.B., Pirani C.L., and D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4 (1994) 1499-1515
28. Pirani C.L., and Olesnicky L. Role of electronmicroscopy in the classification in the classification of lupus nephritis. Am J Kidney Dis 2 (1982) 150-163
29. Tsumagari T., Fukmoto F., Kjnio M., and Tanaka K. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol 16 (1985) 43-49
30. Banfi G., Bertani T., Boeri V., Faraggiana T., Mazzucco G., Monga G., et al. Renal vascular lesions as a marker of a poor prognosis in patients with lupus nephritis. Am J Kidney Dis 18 (1991) 240-248
31. Grishman E., Gerber M.A., and Churg J. Vascular lesions in lupus nephritis. Mod Pathol 1 (1988) 235-241
32. Appel G.B., Williams G.S., Meltzer J.I., and Pirani C.L. Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus. Ann Intern Med 85 (1976) 310-317
33. Stewart Cameron J. Lupus nephritis. J Am Soc Nephrol 10 (1999) 413-424
34. Mori Y., Kishimoto N., Yamahara H., Kijima Y., Nose A., Uchiyama-Tanaka Y., et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus nephritis. Clin Exp Nephrol. 9 (2005) 79-84
35. O'Callaghan C.A. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumat 18 (2004) 411-427
36. Hughes G.R.V., Harris E.N., and Gharavi A.E. The anticardiolipin syndrome. J Rheumatol 13 (1986) 486-489
37. Uthman I., and Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum 35 (2006) 360-367
38. Natejumnong C., Ruangkanchanasetr P., Aimpun P., and Supaporn T. Significance of antiphospholipid antibodies in lupus nephritis. J Med Assoc Thai 89 Suppl 2 (2006) S121-S128
39. Daugas E., Nochy D., Huong D.L., Duhaut P., Beaufils H., Caudwell V., et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13 (2002) 42-52
40. Love P.E., and Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematous (SLE) patients and non-SLE disorders. Ann Intern Med 112 (1990) 682-698
41. Huong D.L., Papo T., Beaufils H., Wechsler B., Bletry O., Baumelou A., et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine 78 (1999) 148-166
42. McCluskey R.T. Lupus nephritis. In: Sommers S.C. (Ed). Kidney Pathology Decennial 1966-1975 (1999), Appleton-Century-Crofts, C.T. East Norwalk 435-445
43. Churg J., and Sobin L.H. Renal Disease: Classification and Atlas of Glomerular Disease, Tokyo, Igaku-Shoin (1982)
44. Pirani C.L., Pollak V.E., and Schwartz F.D. The reproducibility of semiquantitative analysis of renal histology. Nephron 1 (1964) 230-237
45. Morel-Maroger L., Mery J.P., Droz D., Godin M., Verroust P., Kourilsky O., et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 6 (1976) 79-118
46. Austin III H.A., Muenz L.R., Joyce K.M., Antonovych T.T., and Balow J.E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25 (1984) 689-695
47. Schwartz M.M., Lan S.P., Bernstein J., Hill G.S., Holley K., and Lewis E.J. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 21 (1993) 374-377
48. Corwin H.L., Schwartz M.M., and Lewis E. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 8 (1988) 85-93
49. Moroni G., Pasquali S., Quaglini S., Banfi G., Casanova S., Maccario M., et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 3 (1999) 530-539
50. Bajaj S., Albert L., Gladman D.D., Urowitz M.B., Hallett D.C., and Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 12 (2000) 2822-2826
51. Gunnarsson I., Sundelin B., Heimbürger M., Forslid J., van Vollenhoven R., Lundberg I., et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J Rheumatol 4 (2002) 693-699
52. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., and Rohde R.D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 5 (2000) 904-914
53. Nossent J.C., Bronsveld W., and Swaak A.J. Systemic lupus erythematosusIII. Observations on clinical renal involvement and follow-up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48 (1989) 810-816
54. Cortés-Hernández J., Ordi-Ros J., Labrador M., Segarra A., Tovar J.L., Balada E., et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 12 (2003) 287-296
55. Moroni G., Ventura D., Riva P., Panzeri P., Quaglini S., Banfi G., et al. Antiphospholipid antibodies are associated with an increased risk of chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 1 (2004) 28-36
56. Barr R.G., Seliger S., Appel G.B., Zuniga R., D'Agati V., Salmon J., et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 18 (2003) 2039-2046
57. Esdaile J.M., Levinton C., Federgreen W., Hayslett J.P., and Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. QJM 269 (1989) 779-833
58. Esdaile J.M., Joseph L., MacKenzie T., Kashgarian M., and Hayslett J.P. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 21 (1994) 2046-2051
59. Bono L., Cameron J.S., and Hicks J.A. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 4 (1999) 211-218
60. Moroni G., Quaglini S., Maccario M., Banfi G., and Ponticelli C. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 6 (1996) 2047-2053
61. Mok C.C., Ying K.Y., Tang S., Leung C.Y., Lee K.W., Ng W.L., et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50 (2004) 2559-2568
62. Fraenkel L., MacKenzie T., Joseph L., Kashgarian M., Hayslett J.P., and Esdaile J.M. Response to treatment as a predictor of long-term outcome in patients with lupus nephritis. J Rheumatol (1994) 2052-2057
63. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 8 (2006) 2550-2557
64. Boumpas D.T., Austin III H.A., Vaughn E.M., Klippel J.H., Steinberg A.D., Yarboro C.H., et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 (1992) 741-745
65. Austin III H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314 (1986) 614-619
66. Fine D.M. Pharmacological therapy of lupus nephritis. JAMA 293 (2005) 3053-3060
67. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon Garrido E., Danieli M.G., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 12 (2004) 3934-3940
68. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
69. Dooley M.A., Cosio F.G., Nachman P.H., Falkenhain M.E., Hogan S.L., Falk R.J., et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J AmSoc Nephrol 10 (1999) 833-839
70. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343 (2000) 1156-1162
71. Chan T.M., Wong W.S., Lau C.S., Tsang E.W.K., Ji Y.L., Mok M.Y., et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF). J Am Soc Nephrol 12 (2001) 195A
72. Hu W., Liu Z., Chen H., Tang Z., Wang Q., Shen K., et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 115 (2002) 705-709
73. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. N Engl J Med 21 (2005) 2219-2228
74. Chan T.M., Tse K.C., Tang C.S., Mok M.Y., Li F.K., and Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 4 (2005) 1076-1084
75. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 10 (2004) 971-980
76. Houssiau F.A. Management of lupus nephritis; an update. J Am Soc Nephrol 15 (2004) 2694-2704
77. Hu W., Liu Z., Shen S., Li S., Yao X., Chen H., and Li L. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J 116 (2003) 1827-1830
78. Tam L.S., Li E.K., Leung C.B., Wong K.C., Lai F.M., Wang A., et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 8 (1998) 573-580
79. Ferrario L., Bellone M., Bozzolo E., Baldissera E., and Sabbadini M.G. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rhematology 39 (2000) 218-210
80. Tse K.C., Lam M.F., Tang S.C., Tang C.S., and Chan T.M. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 1 (2007) 46-51
81. Moroni G., Maccario M., Banfi G., Quaglini S., and Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 31 (1998) 681-686
82. Mok C.C., Ying K.Y., Lau C.S., Yim C.W., Ng N.W., Wong W.S., et al. Treatment of pure membranous lupus nephropathy with prednisolone and azathioprine: an open label trial. Am J Kidney Dis 2 (2004) 269-276
83. Spetie D.N., Tang Y., Rovin B.H., Nadasdy T., Nadasdy G., Pesavento T.E., et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 6 (2004) 2411-2415
84. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 11 (2004) 3580-3590
85. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 1 (2006) 18-24
86. Bhat P., and Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int 3 (2008) 261-268